Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 6/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6457163 | 0.89 | MMP12 (0.51) | MMP12MMP13SCN10AMAPK1ABL1 | |
| SCHEMBL6880673 | 0.87 | MMP12 (0.58) | MMP12MMP13SCN10AABL1MAPT | |
| SCHEMBL6875530 | 0.83 | MMP12 (0.58) | MMP12MMP13MAPK1ABL1POLB | |
| SCHEMBL8342310 | 0.79 | MMP12 (0.59) | MMP12MMP13SCN10AABL1MAPT | |
| SCHEMBL6879537 | 0.79 | MMP12 (0.55) | MMP12MMP13MAPK1ABL1MAPT | |
| SCHEMBL6882916 | 0.76 | MMP12 (0.55) | MMP12MMP13MAPK1ABL1MAPT | |
| SCHEMBL6881932 | 0.76 | MMP12 (0.59) | MMP12MMP13MAPK1ABL1MAPT | |
| SCHEMBL6450855 | 0.74 | MMP12 (0.55) | MMP12MMP13SCN10AABL1 | |
| SCHEMBL6882182 | 0.74 | MMP12 (0.57) | MMP12MMP13SCN10AMAPK1ABL1 | |
| SCHEMBL6667161 | 0.73 | MMP12 (0.60) | MMP12MMP13MAPK1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | claimed |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | disclosed |
| WO-2004018448-A1 | NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | MMP11, MMP13, CBR1 | MMP12 7/4885MMP13 2/4885SCN10A 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.